Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7970)	12/7/1998 6:17:00 PM
From: Tharos	Respond to of 17367

Tough question to be sure, George. I appears BPI failed to make any difference in one test with monkey's and another with politicians (oops, I meant rats). Given the two failures out of the 100+ BPI tests I have read about (thanks for those links, George), if we construct a right tail Chi-Square distribution test and run it through a one-way ANOVA with equal sample sizes of 1, it appears statistically probable that Clinton did Monica. I can see why RobertS is cautious. But seriously, Yes. Also, if you apply a bit of semantics, it would seem that any immune deficiency may benefit from BPI. This implies a potential AIDS treatment, subject to someone else finding a cure first. RobertS: Xoma is a pharmaceutical company with unproven products in various stages of developments. It should be considered a high-risk, speculative investment.